Literature DB >> 21646559

National Clinical Guideline Centre cost-effectiveness assessment for the National Institute for Health and Clinical Excellence.

David Wonderling1, Laura Sawyer, Elisabetta Fenu, Kate Lovibond, Philippe Laramée.   

Abstract

The National Clinical Guideline Centre (NCGC) develops evidence-based clinical guidelines on behalf of the National Institute for Health and Clinical Excellence (NICE) in the United Kingdom. The U.K. Department of Health has commissioned NICE to make recommendations on the basis of both clinical effectiveness and cost-effectiveness. This article describes how cost-effectiveness is evaluated and accounted for in NCGC guidelines. Six recent case studies are presented, in which consideration of cost-effectiveness has informed recommendations in various ways for clinical guidelines on alcohol use disorders, chronic obstructive pulmonary disease, glaucoma, lower urinary tract symptoms, non-ST-segment elevation myocardial infarction and unstable angina, and venous thromboembolism prophylaxis. Some of the challenges faced in trying to account for cost-effectiveness in clinical guidelines are outlined, as well as some of the difficulties in adapting cost-effectiveness guidelines for other settings.

Entities:  

Mesh:

Year:  2011        PMID: 21646559     DOI: 10.7326/0003-4819-154-11-201106070-00008

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  8 in total

1.  The seen and the unseen: clinical guidelines and cost-effective care.

Authors:  Monica Chang-Panesso; Benjamin D Humphreys
Journal:  J Am Soc Nephrol       Date:  2014-05-29       Impact factor: 10.121

2.  The Cost Effectiveness of Nalmefene for Reduction of Alcohol Consumption in Alcohol-Dependent Patients with High or Very High Drinking-Risk Levels from a UK Societal Perspective.

Authors:  Thor-Henrik Brodtkorb; Melissa Bell; Adam H Irving; Philippe Laramée
Journal:  CNS Drugs       Date:  2016-02       Impact factor: 5.749

3.  The cost-effectiveness of standalone HEPA filtration units for the prevention of airborne SARS CoV-2 transmission.

Authors:  Zafar Zafari; Pedro M de Oliveira; Savvas Gkantonas; Chinenye Ezeh; Peter Alexander Muennig
Journal:  Cost Eff Resour Alloc       Date:  2022-05-12

4.  Epidemiology and Clinical Research Design, Part 2: Principles.

Authors:  Veena Manja; Satyan Lakshminrusimha
Journal:  Neoreviews       Date:  2015

5.  A Systematic Review of Quality of Life Measures in Pregnant and Postpartum Mothers.

Authors:  Mulubrhan F Mogos; Euna M August; Abraham A Salinas-Miranda; Dawood H Sultan; Hamisu M Salihu
Journal:  Appl Res Qual Life       Date:  2013-06-01

Review 6.  Immuno-Oncology Medicines: Policy Implications and Economic Considerations.

Authors:  Georges Adunlin; Stefanie P Ferreri; Jenny Dong; Maisha Kelly Freeman
Journal:  Innov Pharm       Date:  2019-08-08

7.  Integrating clinical and economic evidence in clinical guidelines: More needed than ever!

Authors:  Saskia Knies; Johan L Severens; Werner B F Brouwer
Journal:  J Eval Clin Pract       Date:  2018-04-26       Impact factor: 2.431

8.  A cardiovascular disease policy model: part 2-preparing for economic evaluation and to assess health inequalities.

Authors:  K D Lawson; J D Lewsey; I Ford; K Fox; L D Ritchie; H Tunstall-Pedoe; G C M Watt; M Woodward; S Kent; M Neilson; A H Briggs
Journal:  Open Heart       Date:  2016-06-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.